Statement: Arm 2 of the primary trial receive dose-intensive chemotherapy on a21 day cycle up to 3 times in the absence of disease progression or unacceptable toxicity.
Primary_evidence: INTERVENTION 1:    Arm I   Patients receive dose-intensive chemotherapy comprising doxorubicin hydrochloride IV over 10-15 minutes on day 1, oral cyclophosphamide once daily on days 1-7, and filgrastim subcutaneously on days 2-7. Courses repeat every 7 days for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Beginning 1 week later, patients then receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes once a week for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients with HER-2/neu positive disease also receive trastuzumab IV over 30-90 minutes once a week for 1 year in the absence of disease progression or unacceptable toxicity.   doxorubicin hydrochloride: Given IV   cyclophosphamide: Given orally   filgrastim: Given SC   paclitaxel albumin-stabilized nanoparticle formulation: Given IV   trastuzumab: Given IV   laboratory biomarker analysis: Correlative studies   quality-of-life assessment: Ancillary studies